View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry



  • March 16, 2015

  • This is the title of a recent article by BioCentury’s Steve Usdin. He summarizes how the House Energy & Commerce Committee is putting patient-focused drug development at the top of the 21st Century Cures discussion list. The FDA is backing this and encouraging industry to take an active roll, but how? How do we create a systematic process to capture the voice of the patient in drug development? Thanks to Komathi Stem at Genentech, we introduced one approach through Design Thinking and how it applies to Clinical Trials at the Dpharm USA 2014 event. The purpose of the session was to help people think like the patient. Companies like Genentech that are starting to train their staff in Design Thinking are beaming with the outcome as it relates to innovative ideas with empathy for the patient.

    We are so pleased to bring an entire program dedicated to Design Thinking for Clinical Trials on May 11-12 in Boston. It is an excellent opportunity to roll up our sleeves and dig into each step of design thinking and learn how to apply it to the clinical trial ecosystem with the patient at the center of the process. For more information on the program, click here.

    FDA’s Dr Sumati Nambiar with Komathi Stem, Genentech